Press Release

The Russia's Largest Supplier of Rotavirus Vaccine Launched Clinical Trials of the Latest Generation Meningococcal Vaccine

The drug will be the second vaccine in the Company's portfolio and the first vaccine in Russia with such a set of antigens


The Russian pharmaceutical company Pharm Aid, the largest supplier of rotavirus vaccine in the Russian Federation as of the end of 2022, launched clinical trials of a pentavalent meningococcal vaccine. On February 21, 2023, the Company received permission to conduct the trialsfrom the Ministry of Health of the Russian Federation.Previously, the vaccine had shown its efficacy in laboratory and animal tests, as well as in foreign clinical trialsinvolving volunteers (about 4 thousand people).

The conjugated polysaccharide pentavalent vaccine protects against the world’s most common meningococci of A, C, W, Y, and Xserogroups.Unlike other meningococcal vaccines used in Russia, the drug developed by Pharm Aid includes an additional Xserotype.It is a frequent causative agent of infection in China, Latin America, and the Middle East countriesincluding the UAE, which are popular among Russian tourists; it can also be found in some regions of the Russian Federation.

The clinical trials of the meningococcal vaccine are to be conducted stage-by-stage involvingpeople of all ages, from adults to children 9–12-month old. The vaccine is administered intramuscularly. “Meningococcal infection is a very dangerous disease. The most effective and well-proven way to prevent meningococcal infection remains vaccination of both adults and children.Our Company strives to provide a wider coverage of the population with vaccine prevention, not only for A and C serotypes, but also for X, W, and Y serotypes, especially since the population migration has intensified and our ties with friendly states, that are endemic for these serotypes, have intensely strengthened,” Azamat Metov, Director General of Pharm Aidcomments, “we make every effort to ensure that people in Russia have access to the newest immunobiological drugs. Therefore,as part of our import substitution project,we have entered into agreements with the world’s major vaccine manufacturers from friendly countries. Under these agreements, our Company transfers production technology for innovative biotechnological products from international partners to Russia. This format has already proved its effectiveness in the case of the rotavirus prevention vaccine. We are workingin the same way with other immunobiological drugs, the production of which is to be localized at our plant currently under construction in the Kaluga region.”

Adolescents aged 13–17 years and people over 60 years old are most susceptible to meningococcal infection – this information is provided in the Resolution of the Chief State Sanitary Doctor of the Russian Federation dated December 20, 2018.

For reference:

The pharmaceutical company Pharm Aid was founded in 2017 with the aim of transferring the production technology for innovative biotechnological products to Russia.Today, Pharm Aid is the Russia’s largest supplier of the rotavirus infectionprevention vaccine and plans to build its own production facilities for this and other vaccines, as well asinnovative combined immunobiological drugs for prevention and treatment of various diseases.